tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Vaxcyte provides update on development of VAX-31 pneumococcal vaccine
PremiumThe FlyVaxcyte provides update on development of VAX-31 pneumococcal vaccine
15d ago
Needham ups Vaxcyte target, adds to Conviction List
Premium
The Fly
Needham ups Vaxcyte target, adds to Conviction List
1M ago
Buy Rating on Vaxcyte: De-Risked VAX-31 Clinical Profile, Strong Cash Position, and Attractive Entry Ahead of 2026 Phase 3 Catalyst
Premium
Ratings
Buy Rating on Vaxcyte: De-Risked VAX-31 Clinical Profile, Strong Cash Position, and Attractive Entry Ahead of 2026 Phase 3 Catalyst
1M ago
Vaxcyte announces first participants dosed in OPUS Phase 3 trial of VAX-31
PremiumThe FlyVaxcyte announces first participants dosed in OPUS Phase 3 trial of VAX-31
2M ago
Vaxcyte, Inc. Reports Q3 2025 Financial Results
Premium
Company Announcements
Vaxcyte, Inc. Reports Q3 2025 Financial Results
3M ago
Promising Vaccine Trials and Undervaluation Drive Buy Rating for Vaxcyte
Premium
Ratings
Promising Vaccine Trials and Undervaluation Drive Buy Rating for Vaxcyte
3M ago
Vaxcyte to establish fill-finish manufacturing in North Carolina
PremiumThe FlyVaxcyte to establish fill-finish manufacturing in North Carolina
4M ago
Vaxcyte initiated with a Neutral at Goldman Sachs
Premium
The Fly
Vaxcyte initiated with a Neutral at Goldman Sachs
5M ago
Vaxcyte advances VAX-31 infant Phase 2 study
Premium
The Fly
Vaxcyte advances VAX-31 infant Phase 2 study
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100